[HTML][HTML] Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer.
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer Biology & …, 2022 - search.ebscohost.com
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer biology & … - pubmed.ncbi.nlm.nih.gov
Objective Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the oncogenesis
of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways …
of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways …
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer.
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer Biology & …, 2021 - europepmc.org
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer Biology & …, 2022 - search.proquest.com
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
[HTML][HTML] Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer Biology & …, 2022 - cancerbiomed.org
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
[PDF][PDF] Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang, J He, Y Hu… - 2021 - scholar.archive.org
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
[PDF][PDF] Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang, J He, Y Hu… - 2022 - cancerbiomed.org
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer.
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer Biology & …, 2021 - europepmc.org
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …